Pure Global
NCT06232694

Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

Clinical Study Protocol of Idarubicin, Cytarabine, and Venetoclax -Induced Remission Followed by Consolidation Therapy With Medium-dose Cytarabine Combined With Venetoclax in Newly Diagnosed Adult Acute Myeloid Leukemia
The First Affiliated Hospital with Nanjing Medical University·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Myeloid Leukemia
Drug/Device/Intervention
Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The First Affiliated Hospital with Nanjing Medical University
Location
Nanjing, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2024
End date
Dec 30, 2027
Enrollment
54 participants
Primary outcome

The composite complete remission rate (CR+CRi)

Summary

This study evaluates the efficacy and safety of the combination of idarubicin and cytarabine
 induction followed by intermediate-dose cytarabine consolidation with venetoclax in the
 treatment of newly diagnosed adult acute myeloid leukemia (AML).
 
 This study includes the induction and consolidation phases of AML treatment.

ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06232694
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06232694 through Pure Global AI's free database. This phase not specified trial is sponsored by The First Affiliated Hospital with Nanjing Medical University and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 54 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.